Zatosetron (LY-277,359) is a drug which acts as an
antagonist at the
5HT3receptor[1] It is orally active and has a long duration of action, producing
antinauseant effects but without stimulating the rate of gastrointestinal transport.[2][3] It is also an effective
anxiolytic in both animal studies and human trials,[4] although with some side effects at higher doses.[5][6]
^Cohen ML, Bloomquist W, Gidda JS, Lacefield W (July 1990). "LY277359 maleate: a potent and selective 5-HT3 receptor antagonist without gastroprokinetic activity". The Journal of Pharmacology and Experimental Therapeutics. 254 (1): 350–5.
PMID2366187.
^Robertson DW, Lacefield WB, Bloomquist W, Pfeifer W, Simon RL, Cohen ML (January 1992). "Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships". Journal of Medicinal Chemistry. 35 (2): 310–9.
doi:
10.1021/jm00080a016.
PMID1732548.
^Schwartz SM, Goldberg MJ, Gidda JS, Cerimele BJ (March 1994). "Effect of zatosetron on ipecac-induced emesis in dogs and healthy men". Journal of Clinical Pharmacology. 34 (3): 250–4.
doi:
10.1002/j.1552-4604.1994.tb03994.x.
PMID7517409.
S2CID23486859.
^Smith WT, Londborg PD, Blomgren SL, Tollefson GD, Sayler ME (April 1999). "Pilot study of zatosetron (LY277359) maleate, a 5-hydroxytryptamine-3 antagonist, in the treatment of anxiety". Journal of Clinical Psychopharmacology. 19 (2): 125–31.
doi:
10.1097/00004714-199904000-00006.
PMID10211913.
^Williams PD, Calligaro DO, Colbert WE, Helton DR, Shetler T, Turk JA, Jordan WH (March 1991). "General pharmacology of a new potent 5-hydroxytryptamine antagonist". Arzneimittel-Forschung. 41 (3): 189–95.
PMID1867653.
^Bendele A, Means J, Shoufler J, Schmalz C, Hanasono G, Symanowski J, Adams E (February 1995). "Chronic toxicity of zatosetron, a 5-HT3 receptor antagonist, in rhesus monkeys". Drug and Chemical Toxicology. 18 (1): 61–82.
doi:
10.3109/01480549509017858.
PMID7768200.
Zatosetron (LY-277,359) is a drug which acts as an
antagonist at the
5HT3receptor[1] It is orally active and has a long duration of action, producing
antinauseant effects but without stimulating the rate of gastrointestinal transport.[2][3] It is also an effective
anxiolytic in both animal studies and human trials,[4] although with some side effects at higher doses.[5][6]
^Cohen ML, Bloomquist W, Gidda JS, Lacefield W (July 1990). "LY277359 maleate: a potent and selective 5-HT3 receptor antagonist without gastroprokinetic activity". The Journal of Pharmacology and Experimental Therapeutics. 254 (1): 350–5.
PMID2366187.
^Robertson DW, Lacefield WB, Bloomquist W, Pfeifer W, Simon RL, Cohen ML (January 1992). "Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships". Journal of Medicinal Chemistry. 35 (2): 310–9.
doi:
10.1021/jm00080a016.
PMID1732548.
^Schwartz SM, Goldberg MJ, Gidda JS, Cerimele BJ (March 1994). "Effect of zatosetron on ipecac-induced emesis in dogs and healthy men". Journal of Clinical Pharmacology. 34 (3): 250–4.
doi:
10.1002/j.1552-4604.1994.tb03994.x.
PMID7517409.
S2CID23486859.
^Smith WT, Londborg PD, Blomgren SL, Tollefson GD, Sayler ME (April 1999). "Pilot study of zatosetron (LY277359) maleate, a 5-hydroxytryptamine-3 antagonist, in the treatment of anxiety". Journal of Clinical Psychopharmacology. 19 (2): 125–31.
doi:
10.1097/00004714-199904000-00006.
PMID10211913.
^Williams PD, Calligaro DO, Colbert WE, Helton DR, Shetler T, Turk JA, Jordan WH (March 1991). "General pharmacology of a new potent 5-hydroxytryptamine antagonist". Arzneimittel-Forschung. 41 (3): 189–95.
PMID1867653.
^Bendele A, Means J, Shoufler J, Schmalz C, Hanasono G, Symanowski J, Adams E (February 1995). "Chronic toxicity of zatosetron, a 5-HT3 receptor antagonist, in rhesus monkeys". Drug and Chemical Toxicology. 18 (1): 61–82.
doi:
10.3109/01480549509017858.
PMID7768200.